Ilan Matok

Oct 26, 2024 | onlinelibrary.wiley.com | Hagar Cohen |Bruria Hirsh Raccah |Ilan Matok |Nahawand Bahash

The magnitude of CYP3A induction has been shown to predict the change in exposure to P-gp substrates. Exposure to dabigatran is not predicted to be considerably affected by low or moderate oxcarbazepine, eslicarbazepine, clobazam, and rufinamide doses.

Nov 27, 2023 | onlinelibrary.wiley.com | Hagar Cohen |Ghadeer Mahajna |Tomer Ben-Shushan |Ilan Matok

Newer ASMs can considerably affect the exposure to CYP3A substrates. The magnitude of cenobamate's effect on CYP3A partially overlaps with that of phenytoin. The available data may underestimate the effects of some ASMs at their maximal recommended doses on CYP3A activity. Prescribers should be aware of the CYP3A induction potential of several newer ASMs, which may manifest only after upward titration of the dose.